GRIA3 Protein

GRIA3 Protein

Introduction

Gria3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background: #2c3e50; color: white; text-align: center;">GRIA3 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Glutamate Ionotropic Receptor AMPA Type Subunit 3 (GluA3)</td></tr>
<tr><td><strong>Gene</strong></td><td>[GRIA3](/genes/gria3)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P42263](https://www.uniprot.org/uniprot/P42263)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~98 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Postsynaptic membrane, synapse</td></tr>
<tr><td><strong>Protein Family</strong></td><td>AMPA receptor family, ionotropic glutamate receptor family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/schizophrenia" style="color:#ef9a9a">Schizophrenia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">15 edges</a></td>
</tr>
</table>
</div>

Overview

...

GRIA3 Protein

Introduction

Gria3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background: #2c3e50; color: white; text-align: center;">GRIA3 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Glutamate Ionotropic Receptor AMPA Type Subunit 3 (GluA3)</td></tr>
<tr><td><strong>Gene</strong></td><td>[GRIA3](/genes/gria3)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P42263](https://www.uniprot.org/uniprot/P42263)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~98 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Postsynaptic membrane, synapse</td></tr>
<tr><td><strong>Protein Family</strong></td><td>AMPA receptor family, ionotropic glutamate receptor family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/schizophrenia" style="color:#ef9a9a">Schizophrenia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">15 edges</a></td>
</tr>
</table>
</div>

Overview

GRIA3 encodes the glutamate ionotropic receptor AMPA type subunit 3 (GluA3), one of four AMPA receptor subunits (GluA1-4) that form ionotropic glutamate receptors in the central nervous system. AMPA receptors mediate fast excitatory synaptic transmission and are critical for synaptic plasticity, learning, and memory.

Structure

GluA3 is a transmembrane protein consisting of:

• N-terminal extracellular domain (ligand-binding domain)
• Three transmembrane domains
• Intracellular C-terminal tail
• Forms tetramers (homo- or heterotetramers with other GluA subunits)

The ligand-binding domain contains the glutamate binding site, while the C-terminal tail interacts with PDZ domain proteins for synaptic targeting.

Normal Function

AMPA receptors containing GluA3 subunits mediate fast excitatory neurotransmission at the vast majority of synapses in the brain. These receptors are essential for:

• Synaptic plasticity ([LTP](/mechanisms/long-term-potentiation) and LTD)
• Learning and memory
• Neural development
• Behavior and cognition

GluA3-containing receptors show distinctive trafficking properties and are involved in synaptic scaling.

Role in Disease

Alzheimer's Disease

Reduced GRIA3 expression and altered AMPA receptor trafficking have been reported in AD brains. This may contribute to synaptic dysfunction and memory impairment.

Amyotrophic Lateral Sclerosis

Dysregulation of AMPA receptor function contributes to excitotoxicity in motor [neurons](/entities/neurons). Altered GluA3 subunit composition may affect calcium permeability.

X-linked mental retardation

Pathogenic mutations in GRIA3 cause X-linked mental retardation with impaired synaptic plasticity.

Therapeutic Targeting

Current therapeutic approaches include:

• AMPA receptor modulators: Positive allosteric modulators to enhance receptor function
• Targeted gene therapy: Viral vector delivery to restore receptor expression
• Small molecule stabilizers: Compounds to improve receptor trafficking

Key Publications

^[1] AMPA receptor subunit expression in AD brain. Neurobiol Aging. 2003.^[2] GRIA3 and X-linked mental retardation. Nat Genet. 2000.^[3] AMPA receptor dysfunction in ALS. Exp Neurol. 2012.

Molecular Mechanisms

Receptor Properties

• Calcium permeability: GluA3 homomers are Ca2+-permeable
• Conductance: ~10 pS per subunit
• Kinetic properties: Fast activation and desensitization
• Gating: Ligand-binding domain conformational changes

Trafficking

• Synaptic targeting: GRIP/ABP and PICK1 PDZ interactions
• Endocytosis: Activity-dependent internalization
• Trafficking cycle: Continuous recycling at synapses
• [LTP](/mechanisms/long-term-potentiation)/LTD: Activity-dependent insertion/removal

Animal Models

Knockout Studies

• Gria3 null mice: Viable with subtle behavioral deficits
• Humanized mice: Expressing patient mutations
• Conditional knockouts: Brain region-specific deletion

Key Findings

Synaptic plasticity requires GluA3-containing receptors

Motor learning impaired in Gria3 knockout

Social behavior deficits in some models

Compensatory upregulation of other AMPA subunits

Therapeutic Targeting

Current Approaches

• Positive allosteric modulators: Ampakines
• Channel blockers: Protecting against excitotoxicity
• Gene therapy: Restoring receptor function

Challenges

• Subunit selectivity is difficult
• Brain penetration
• Side effects from broad modulation

Neurodegenerative Connections

Parkinson's Disease

• AMPA receptor changes in substantia nigra
• Excitotoxicity in dopaminergic neurons
• Therapeutic targeting potential

Huntington's Disease

• mHTT effects on AMPA receptor trafficking
• Synaptic dysfunction contribution
• Cognitive deficits correlation

ALS

• AMPA receptor dysfunction in motor neurons
• Calcium permeability contribution to vulnerability
• Therapeutic targeting actively investigated

See Also

• [Genes/GRIA3](/genes/gria3)
• [Diseases/Alzheimer's Disease](/diseases/alzheimers-disease)
• [Diseases/Amyotrophic Lateral Sclerosis](/diseases/als)
• [Mechanisms/Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)

External Links

• [UniProt](https://www.uniprot.org/uniprot/P42263)
• [NCBI Protein](https://www.ncbi.nlm.nih.gov/protein/P42263)
• [PDB](https://www.ebi.ac.uk/pdbe/search/?q=P42263)

Background

The study of Gria3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] AMPA receptor subunit expression in AD brain. Neurobiol Aging. 2003.^[2] GRIA3 and X-linked mental retardation. Nat Genet. 2000.^[3] AMPA receptor dysfunction in ALS. Exp Neurol. 2012.

Pathway Diagram

The following diagram shows the key molecular relationships involving GRIA3 Protein discovered through SciDEX knowledge graph analysis: